selective S1PR2 antagonist preclin. candidate

oral efficacy (1 mpk BID) in fibrosis model

scaffold hop from literature starting points

J. Med. Chem., May 3, 2021

Galapagos NV, Mechelen, Belgium

The Galapagos S1PR2 antagonist GLPG2938 is a preclinical candidate intended for the treatment of idiopathic pulmonary fibrosis (IPF). Though several S1PR1 modulators have been approved, no selective S1PR2 antagonist has entered…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.